



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**23 June 2016**

---

## **Bionomics Receives Share of Funds from License Deal for Cancer and Blood Disorder Inhibitors**

**ADELAIDE, AUSTRALIA, 23 June 2016:** Australian drug development company Bionomics Limited (ASX:BNO, OTCQX:BNOEF) has received US\$736,815 in licensing funds as part of an agreement between MSD (known as Merck in the US & Canada) and Cancer Research Technologies (CRT) on behalf of the Australian Cooperative Research Centre for Cancer Therapeutics (CTx).

The payment by MSD represents part of an exclusive licensing agreement for the development of protein arginine methyltransferase 5 (PRMT5) inhibitors with CTx – a Melbourne-based Cooperative Research Centre developing novel therapies for cancer.

High levels of PRMT5 are found in mantle cell lymphoma, chronic lymphocytic leukaemia, melanoma, lung and breast cancers and are linked to low survival rates. PRMT5 inhibitors also have application potential in treating non-cancer blood disorders such as sickle cell disease and beta thalassemia by initiating genes involved in the development of blood.

This receipt of funds by Bionomics is part of an initial payment of US\$15 million to CRT, with total deal future milestone payments potentially reaching US\$500 million alongside additional royalty payments on sales.

As part of the agreement payments are shared between CRT, the Wellcome Trust, CTx and CTx's Australian research partners including Bionomics. Bionomics will be a potential beneficiary of future milestone payments and royalties.

Under the license agreement MSD is responsible for research and development, clinical development, regulatory approvals and worldwide commercialisation of products.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

**Australia**  
Monsoon Communications  
Rudi Michelson  
+613 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**US**  
Stern IR, Inc.  
Beth Del Giacco  
+1 212 362 1200  
[beth@sternir.com](mailto:beth@sternir.com)

### **About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

[www.bionomics.com.au](http://www.bionomics.com.au)

### **About Cancer Therapeutics CRC**

Cancer Therapeutics CRC (CTx) is in the business of finding cures for cancer. Founded in 2007 and funded by the Cooperative Research Centre (CRC) Programme, CTx is collaborative partnership of leading Research Institutes, Universities and biotechnology companies that translates Australia's innovative research discoveries into new cancer drugs ready for clinical development. In particular it is targeting novel cancer pathways associated with the process of metastasis and children's cancers. Further information about CTx can be found at [www.cancercrc.com](http://www.cancercrc.com)

The CRC Programme supports industry led end-user driven research collaborations to address the major challenges facing Australia. Australia's network of CRCs operates across all sectors of Australia's economy and society. Further information about the CRC Programme is available [www.business.gov.au](http://www.business.gov.au)

### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.